CleaRank Financial AI • AI-powered analysis using real-time market data from TwelveData
Analysis reviewed by Michelle Sofia, Market Analyst. Data refreshed daily. Not financial advice.
MetLife, Inc. (MET) is trading at $99.72, above its 50-day SMA of $96.77 and 200-day SMA of $84.42, indicating positive short-to-medium term momentum. The company's recent earnings beat, with actual EPS of $2.43 exceeding estimates of $2.29 by 6.11%, further supports this upward trend. Analysts maintain a generally positive outlook, with a consensus rating of Buy and a median price target of $109.50, suggesting a potential upside of 9.8% from current levels. Fundamentally, MetLife's profit margin of 4.57% and return on equity of 13.09% are competitive within the Financial Services sector, though its P/E ratio of 19.19 is slightly above the sector median of 16.5. The company's revenue growth of 10.5% aligns with the sector average of 11.7%. Key risks include the moderate insider selling signal and potential shifts in interest rate environments impacting insurance profitability.
MET at a glance
MetLife, Inc. (MET): Buy, 72/100 on CleaRank's AI score.
TrendUp: the price is above both its 50- and 200-day moving averages ($96.77 and $84.42).
InsidersInsiders sold $3.8M and made no open-market purchases over the last 18 months.
ValuationP/E of 19.2 against 16.5 for the Financial Services sector: broadly in line with peers (+16%).
As of October 15, 2026, MetLife, Inc. (MET) trades at $99.72. Wall Street's consensus target is $109.50 across 18 analysts. The 14-day RSI (daily closes) is 60, showing bullish momentum without being overbought, and the price is above its 50-day simple moving average of $96.77.
Figures as of October 15, 2026.
Only on CleaRank
Figures we compute ourselves from MET's own price, earnings and insider-filing history. Tap one to see it in context.
Valuation is broadly in line with sector peers (16% difference), suggesting fair market pricing relative to industry standards.
MET Financial Performance
Revenue vs. Earnings
Annual
Quarterly
Earnings Reality Check
In the last quarter, MET beat the analyst estimate 1 time; the stock rose in the first session after every beat.
MET earnings surprises and the stock's reaction
Report
EPS estimate
EPS actual
Surprise
First session
5 sessions
Aug 5, 2026
$2.29
$2.43
+6.11%
+3.83%
+0.42%
The first session is the first full trading day on the news: the report day itself for a report before the open, the next day for one after the close. Surprise is actual EPS against the consensus estimate.
As of October 15, 2026, MET has beaten the analyst EPS estimate in 1 of its last 1 reported quarters and rose in the first trading session after that beat; its latest report, on August 5, 2026, came in 6.11% above the estimate and the stock moved +3.83% in the first session.
MET Analysis
Company's Health4/5
12-Month Analyst Target+9.81% above price
Median of 18 analysts (12-month)
$109.50
AI Analyst Consensus ScoreBuy
MetLife, Inc. (MET) exhibits bullish momentum, with its 14-day RSI at 60.1, indicating strength without being overbought. The stock is trading above its 20-day EMA ($97.50), 50-day SMA ($96.77), and 200-day SMA ($84.42), suggesting an upward trend is firmly in place. The MACD at 0.84 further supports this positive technical picture. Key support levels are established around the 50-day SMA at $96.77 and the 20-day EMA at $97.50. Resistance is likely to be tested near the recent highs, with the median analyst target price of $109.50 serving as a significant psychological and potential price objective. Volume has been above average recently, with a 12.1% increase, indicating strong investor interest.
ProTips
MetLife's recent earnings beat of 6.11% and positive RSI momentum suggest continued strength, but monitor insider selling closely.
The stock is trading above its 50-day and 200-day moving averages ($96.77 and $84.42), indicating a bullish trend, with support near the 50-day SMA at $96.77.
Key Catalysts
BullishRecent Earnings Beat
MetLife reported EPS of $2.43, exceeding estimates by 6.11% and driving a 3.83% stock price increase, indicating strong operational performance.
Source: Company PR
BullishPositive Analyst Ratings
18 analysts cover MetLife with a consensus 'Buy' rating and a median price target of $109.50, suggesting a 9.8% upside potential.
Source: Wall Street Summary
BearishModerate Insider Selling
Insiders have sold $3.8 million worth of shares, signaling a moderate sell-off which could indicate caution among management regarding near-term stock performance.
Source: Insider Transactions
NeutralSector Performance
MetLife operates in the Financial Services sector, which has a median P/E of 16.5 and revenue growth of 11.7%, providing a benchmark for its performance.
Source: Sector Averages
Market Outlook
MetLife, Inc. (MET) is expected to continue its positive trajectory, with analysts projecting earnings per share to reach $11.15 in the next year, reflecting a projected growth rate of approximately 10.03%. Key catalysts for upside include continued strong earnings performance and favorable market conditions for the insurance sector. Conversely, significant interest rate hikes or a severe economic recession could negatively impact investment returns and policyholder behavior, posing downside risks to the outlook. The moderate insider selling also warrants attention as a potential indicator of near-term caution.
Key Statistics
Market Cap
63.37B
P/E Ratio
19.19
EPS (TTM)
5.22
Dividend Yield
2.33%
52 Week High
101.44
52 Week Low
67.33
As of October 15, 2026, MET trades at $99.72, with a market value of $63.37B, a P/E ratio of 19.19 and a dividend yield of 2.33%.
MetLife, Inc. (MET) trades at a P/E ratio of 19.19, which is slightly above the sector median of 16.5, suggesting a modest premium valuation. However, its price-to-sales ratio of 0.80 is competitive, and its return on equity at 13.09% is in line with the sector average of 13.8%. The company's profit margin stands at 4.57%, and its operating margin is 5.52%. With a revenue growth rate of 10.5%, MetLife is performing comparably to the sector average of 11.7%. The company's debt-to-equity ratio of 1.80 is also consistent with sector averages. While the P/E ratio suggests a slight premium, the solid profitability and revenue growth metrics provide a fundamental basis for the current valuation.
Earnings & Growth Analysis
MetLife, Inc. (MET) recently reported earnings for the period ending August 5, 2026, with actual EPS of $2.43, surpassing the analyst estimate of $2.29 by 6.11%. This beat contributed to a 3.83% increase in the stock price on the reporting date. The company has demonstrated a pattern of meeting or exceeding earnings expectations in its recent reporting periods.
Key Risks
MetLife, Inc. (MET) faces moderate selling pressure from insiders, with $3.8 million in sales across recent filings, indicating a potential cautionary signal. While the company's valuation is not excessively stretched, its P/E ratio is slightly above the sector median. Also, the insurance industry is sensitive to macroeconomic factors such as interest rate fluctuations and economic downturns, which could impact profitability and investment returns.
Technical Indicators i
RSI (14-day)
60.08
MACD (12, 26)
0.838
SMA (50-day)
96.77
SMA (200-day)
84.42
Technical RatingBullish
RSI
Bullish
SMA Cross
Bullish
Price vs SMA
Bullish
MACD
Bullish
Golden Cross in effect with the 50-day SMA ($96.77) above the 200-day SMA ($84.42), price action is firmly bullish above key moving averages.
As of October 15, 2026, with MET at $99.72, its 14-day RSI is 60.1 (showing bullish momentum without being overbought), its 50-day simple moving average is $96.77 and its 200-day is $84.42.
Calculated by CleaRank on daily closes as of October 15, 2026: Wilder's 14-day RSI, 50- and 200-day simple moving averages, MACD line (12, 26).
Market Correlations
How this stock moves relative to other assets
Based on 1 year of daily price data. Correlations may vary over different time periods.
S&P 500 (SPY)+0.60
Moderate correlation
Nasdaq 100 (QQQ)+0.43
Moderate correlation
Bitcoin (BTC)+0.23
Weak correlation
Gold (XAU)+0.02
Weak correlation
As of October 15, 2026, MET's 1-year correlation of daily returns is +0.60 with S&P 500 (SPY), +0.43 with Nasdaq 100 (QQQ), +0.23 with Bitcoin (BTC) and +0.02 with gold (XAU).
Check Custom Correlation
How does any other asset move with MET? One year of daily closes, Pearson correlation.
Try
MET Wall Street View
12-month price targets
Low $84.00Median $109.50 (+9.8%)High $119.00
Ratings
Buy 13Hold 4Sell 13 months ago: 12 of 18 buy
Recent rating actions
Recent analyst rating actions on MET
Date
Firm
Action
Rating
Oct 7, 2026
Mizuho
Maintains
Outperform
Oct 7, 2026
Barclays
Maintains
Overweight
Oct 6, 2026
UBS
Maintains
Buy
Oct 5, 2026
TD Cowen
Maintains
Buy
Sep 22, 2026
Piper Sandler
Upgrade
Overweight
Aug 24, 2026
Morgan Stanley
Maintains
Overweight
As of October 15, 2026, 18 Wall Street analysts cover MET: 13 rate it a buy or strong buy, 4 a hold and 1 a sell or strong sell. Their 12-month price targets range from $84.00 to $119.00, with a median of $109.50, 9.8% above the price of $99.72.
Source: TwelveData analyst consensus. Targets and ratings belong to the analysts, not to CleaRank.
MET Trade Plans
Specific entry, exit, and risk management levels
Select Your Trade Bias
Risk Tolerance
Conservative2%Aggressive
Portfolio Value
$
Position Size: Enter portfolio size →
Long entry pick an entry style
Conservative
$97.73
2% below current price (Pullback entry)
Lower risk, wait for pullback
Aggressive
$99.72
Buy at current price
Higher risk, immediate entry
Risk Management
STOP LOSS
$94.79
MAX LOSS
-3.0%
Volatility-Adjusted Stop Loss
Calculated based on RSI (60.1) and current market volatility
These levels come from MET's moving averages and recent volatility, not from a forecast. Educational levels, not financial advice; the full disclaimer is at the foot of the page.
Growth of $10,000
A $10,000 investment in MET in October 2016 would be worth about $23,974 today, compared with about $36,237 for the same investment in the S&P 500 benchmark. This is price change only; dividends paid along the way would add to it.
Compare with Another Ticker
MET Drawdowns & Recovery
Worst fall, last 10 years
-50.9%
November 2017 to March 2020
Recovery
11 months
back at the old peak by February 2021
From the 10-year high
-0.9%
highest close, October 2026
1-year holds that gained
60%
of every 1-year window
As of October 15, 2026, MET's worst peak-to-trough fall over the last 10 years was -50.9% (November 2017 to March 2020); it regained that peak by February 2021, 11 months after the low, and 60% of 1-year holding periods ended with a gain.
From weekly closing values. A drawdown is the fall from the highest value reached so far to a later low.
Monte Carlo Projection (10yr)
CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in MET today could grow to about $20,496 by 2036 in the base case, with a 90th-percentile outcome near $69,408 and a 10th-percentile outcome around $6,053. The simulation models price only; at today's 2.33% yield, dividends would add to these figures. Projections are statistical simulations, not guarantees.
MET Stock Price Prediction: 2030
CleaRank's simulation projects a price near $133 for MET by 2030 in the base case, from $99.72 today (1.3x over 4 years). The 10th-percentile path ends near $61.44. These are outcomes of a Monte Carlo simulation run on MET's historical return distribution, not price targets, and they assume no dividends are reinvested.
MET simulated price paths by year
Year
10th percentile
Base case
90th percentile
2027
$72.85
$107
$158
2028
$66.71
$115
$199
2029
$63.41
$124
$241
2030
$61.44
$133
$287
2031
$60.26
$143
$338
Method: a lognormal simulation of MET's own volatility and capped historical trend, re-run daily; base case is the median path, the outer columns the 10th and 90th percentiles.
As of October 15, 2026, MET insiders reported 2 open-market sales worth $3.8M and no open-market purchases over the last 18 months; grants and option exercises are not counted.
Recent insider transactions in MET
Date
Insider
Type
Shares
Value
Oct 1, 2026
GLASER DANIEL S
Director
Grant
544
$51.3K
Oct 1, 2026
HARRIS CARLA A
Director
Grant
544
$51.3K
Oct 1, 2026
HAY LAURA J
Director
Grant
544
$51.3K
Oct 1, 2026
HUBBARD ROBERT GLENN
Director
Grant
941
$88.8K
Oct 1, 2026
JOHNSON JEH CHARLES
Director
Grant
544
$51.3K
Oct 1, 2026
KENNARD WILLIAM E
Director
Grant
544
$51.3K
Oct 1, 2026
MCKENZIE DIANA L
Director
Grant
544
$51.3K
Oct 1, 2026
MUMENTHALER CHRISTIAN STEPHANE
Director
Grant
544
$51.3K
Oct 1, 2026
SEITZ MICHELLE
Director
Grant
544
-
Oct 1, 2026
WEINBERGER MARK A
Director
Grant
544
-
Page 1 of 1
Frequently Asked Questions
What is MetLife's long-term outlook?
MetLife's long-term outlook is positive, with analysts projecting earnings per share to grow to $11.15 next year and an average annual growth rate of 6.3% over the next five years. The company's solid financial footing and competitive positioning in the insurance sector support this view.
What are the key growth drivers for MetLife?
MetLife's growth is driven by its diversified insurance and financial services offerings. The company is expected to see revenue growth of approximately 1.00% this year and 4.00% next year, supported by strategic initiatives and market demand.
How does MetLife's valuation compare to its peers?
MetLife's P/E ratio of 19.19 is slightly higher than the sector median of 16.5, but its return on equity of 13.09% is competitive with the sector average of 13.8%. Its price-to-sales ratio of 0.80 is also in line with industry averages.
What is the current analyst sentiment on MetLife stock?
The current analyst sentiment for MetLife (MET) is predominantly positive, with a 'Buy' consensus rating from 18 analysts. The median price target is $109.50, indicating an expected upside of 9.8% from the current price.
What are the main risks facing MetLife?
Key risks for MetLife include moderate insider selling totaling $3.8 million and the inherent sensitivity of the insurance industry to interest rate changes and economic downturns. Its P/E ratio is also slightly above the sector median.
Does MET pay a dividend?
Yes. As of October 15, 2026, MET's dividend yield is 2.33%, or about $2.32 per share a year at the current price of $99.72. Yields move with the share price and with changes to the payout.
Is MET in an uptrend?
Yes. MetLife, Inc. (MET) trades at $99.72, above both its 50- and 200-day moving averages ($96.77 and $84.42). Its 14-day RSI on daily closes is 60.1, showing bullish momentum without being overbought.
Are insiders buying or selling MET?
Selling, on balance. In the last 18 months, MET's officers, directors and large holders reported 2 sales worth $3.8M and no open-market purchases. Grants and option exercises are not counted as buying.
What is the analyst price target for MET?
As of October 15, 2026, the 18 Wall Street analysts covering MET have 12-month targets from $84.00 to $119.00, with a median of $109.50, 9.8% above the current price of $99.72. 13 rate it a buy or strong buy, 4 a hold and 1 a sell or strong sell. Three months ago 12 of 18 rated it a buy.
What is MET's biggest drop in the last 10 years?
MetLife, Inc. (MET)'s worst peak-to-trough fall over the last 10 years was -50.9%, from November 2017 to March 2020. It regained that peak by February 2021, 11 months after the low. Over the same period, 60% of 1-year holding periods ended with a gain.
